News
-
09.02.2010
Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C - -
04.02.2010
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer
| Manufacturing |
At our cGMP production facility, inspected by the United States Food and Drug Administration (FDA) and Swissmedic, we can produce small batches of drug products for feasibility studies, through clinical trial supplies onto commercial scale manufacturing. We have extensive experience with both small molecule pharmaceuticals and biologics. Throughout the entire chain, we develop, conduct and control production processes to ensure that our products conform to specifications and respect international Good Laboratory Practice (cGLP) and cGMP guidelines. |



